Although this term in principle refers to inhibitors of any member of the PARP family of enzymes, most relevant for cancer therapy are those targeting PARP1 and PARP2, which are primarily involved in DNA repair (Lüscher et al., 2021). Here, PARP1 is linked to cancer.